Allergan, InnoCore to develop sustained release injectable drugs

InnoCore Pharmaceuticals and Allergan, Inc., have signed an exclusive agreement to formulate Allergan ophthalmic drugs using InnoCore’s sustained release drug delivery platform.

This agreement expands their existing collaboration to develop long-acting ocular drug delivery products for the treatment of ophthalmic diseases.

InnoCore will use its patented SynBiosys polymeric drug delivery platform to create versions of Allergan's proprietary drugs capable of sustained release for many months following a single ocular injection.

The SynBiosys drug delivery platform is based on novel biodegradable multi-block co-polymers with unique molecular architectures that allow precise and site-specific delivery of drugs for predetermined periods, ranging from weeks to many months.